
Please try another search
By Oliver Gray Investing.com - The S&P/ASX 200 fell 91.5 points or 1.24% to 7312.2 in early trade, extending losses of 0.2% last week and trading at 9-week lows as falling Iron ore prices continued to...
Feb 22 (Reuters) - Zelira Therapeutics Ltd ZLD.AX : * HY LOSS ATTRIBUTABLE $3.6 MILLION VERSUS LOSS OF $2.6 MILLION
Feb 15 (Reuters) - Zelira Therapeutics Ltd ZLD.AX : * OLUDARE ODUMOSU TO ASSUME ROLE OF GLOBAL MANAGING DIRECTOR * RICHARD HOPKINS TO STEP-DOWN AS CEO AND MANAGING DIRECTOR EX-USA
Dec 14 (Reuters) - Zelira Therapeutics Ltd ZLD.AX : * ENTERED LICENSING AGREEMENT WITH ALTERNATIVE SOLUTIONS LLC * DEAL TO MANUFACTURE, DISTRIBUTE ZELIRA'S HOPE™ PRODUCTS * WILL RECEIVE UPFRONT FEE &...
Sept 23 (Reuters) - Zelira Therapeutics Ltd ZLD.AX : * SECURED A $2 MILLION STRATEGIC INVESTMENT FROM THORNEY INVESTMENT GROUP * THORNEY INVESTMENT GROUP INCREASES EXISTING HOLDING TO BECOME...
Sept 8 (Reuters) - Zelira Therapeutics Ltd ZLD.AX : * FORMS SUBSIDIARY TO LAUNCH NEW HEMP DERIVED CANNABINOID-BASED ORAL CARE PRODUCTS IN USA Source ( https:// Further company coverage: ZLD.AX
Aug 28 (Reuters) - Zelira Therapeutics Ltd ZLD.AX : * FY LOSS $7.0 MILLION VERSUS LOSS $3.6 MILLION
July 30 (Reuters) - Zelira Therapeutics Ltd ZLD.AX : * ZELIRA THERAPEUTICS- ON-TRACK TO LAUNCH ZENIVOL AND HOPE RANGE OF PRODUCTS INTO AUSTRALIAN MARKET BY END OF Q3
July 29 (Reuters) - Zelira Therapeutics Ltd ZLD.AX : * REQUEST TRADING HALT PENDING ANNOUNCEMENT IN RELATION TO A CAPITAL RAISING
July 22 (Reuters) - Zelira Therapeutics Ltd ZLD.AX : * ZELIRA THERAPEUTICS ENTERS AGREEMENT WITH CARDIOVASCULAR SOLUTIONS OF CENTRAL MISSISSIPPI TO DEVELOP PRODUCTS * ZELIRA THERAPEUTICS - UNDER...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review